modelBloodPlasma
Extends from Pharmacolibrary.Drugs.ATC.B.B05AX03.
Information
| name: | BloodPlasma | |
| ATC code: | B05AX03 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 0.05 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Blood plasma is the liquid component of blood that serves as a medium for transporting nutrients, hormones, and waste products throughout the body. It is used therapeutically in plasma transfusions to treat patients with clotting disorders, trauma, burns, or in cases of massive blood loss. It is an approved and commonly used blood product in modern medicine.
Pharmacokinetics
Not applicable, as pharmacokinetic (PK) modeling in the classical sense (absorption, distribution, metabolism, excretion) is not standard for administered human plasma, which does not behave as a classical small molecule drug. Plasma is administered as a fluid replacement, and its behavior is governed by volume kinetics rather than traditional PK.
References
Kim, P, et al., & Garofolo, PM (2024). Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. The Lancet. Infectious diseases 24(12) 1319–1332. DOI:10.1016/S1473-3099(24)00424-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39134085
Mairinger, S, et al., & Kuntner, C (2020). Plasma pharmacokinetic and metabolism of [. Nuclear medicine and biology 84-85 28–32. DOI:10.1016/j.nucmedbio.2020.01.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31981857
Abu Bakar, A, et al., & Lyall, H (2025). Dosing, Toxicity and Drug Concentrations for Ganciclovir/Valganciclovir in Preterm and Low Birthweight Infants Treated for Cytomegalovirus. The Pediatric infectious disease journal 44(4) 319–325. DOI:10.1097/INF.0000000000004605 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40063966
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)